Home › Funds › Prosight Management, LP › LKFT

Prosight Management, LP position in LKFT

LAKEFRONT BIOTHERAPEUTICS NV

Prosight Management, LP reported holding 1,998,400 shares of LKFT (LAKEFRONT BIOTHERAPEUTICS NV) in its Q3 2026 13F filing — a position valued at US$59.3M, representing 11.49% of its reported portfolio and ranking #1 among its reported holdings. Prosight Management, LP has disclosed LKFT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)2.00M sh
Reported value held$59.25M
Portfolio Weight11.49%
First reportedQ3 2023
Last changeReduce
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Prosight Management, LP's LKFT position evolved

Prosight Management, LP first disclosed a stake in LKFT in Q3 2023 at 730,207 shares (US$25.2M). The position peaked in Q2 2026 at 2,043,344 shares, worth US$61.3M. Across 13 filings, Prosight Management, LP increased the stake 7 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 1,998,400 shares valued at US$59.3M — a reduction of -44,944 shares quarter over quarter.. Notable position changes include a 45% increase in Q2 2024 (shares rose 16% over the following quarter), a 35% trim in Q3 2025 (shares fell 6% over the following quarter), a 44% increase in Q1 2026 (shares were roughly flat over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 730.21K $25.23M New
Q4 2023 827.29K $33.63M Add
Q1 2024 931.51K $29.99M Add
Q2 2024 1.35M $33.45M Add
Q3 2024 1.03M $29.62M Reduce
Q4 2024 1.02M $28.19M Hold
Q1 2025 1.31M $33.03M Add
Q2 2025 1.77M $49.64M Add
Q3 2025 1.15M $39.84M Reduce
Q4 2025 1.07M $35.12M Reduce
Q1 2026 1.55M $46.50M Add
Q2 2026 2.04M $61.26M Add
Q3 2026 2.00M $59.25M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About LKFT and 13F data

LKFT (LAKEFRONT BIOTHERAPEUTICS NV) is a company whose sector is not yet classified in our data. 20 other funds we track also report a position in LKFT — the largest reported positions include GILEAD SCIENCES, INC. (US$501.3M), TANG CAPITAL MANAGEMENT LLC (US$113.5M), Madison Avenue Partners, LP (US$103.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding LKFT

All LKFT fund holders →

FAQ

How long has Prosight Management, LP held LKFT?

Prosight Management, LP has disclosed LKFT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Prosight Management, LP's current position in LKFT?

As of Q3 2026, Prosight Management, LP holds 2.00M shares of LKFT (LAKEFRONT BIOTHERAPEUTICS NV), valued at $59.25M, representing 11.49% of its reported portfolio and ranking #1.

Has Prosight Management, LP been buying or selling LKFT?

In the latest 13F filing (Q3 2026), Prosight Management, LP reduced its position in LKFT. The position peaked in Q2 2026 at 2.04M shares.

Which other funds hold LKFT?

Other major institutional holders of LKFT include GILEAD SCIENCES, INC., TANG CAPITAL MANAGEMENT LLC, Madison Avenue Partners, LP, among 20 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.